Schultze Special Purpose Acquisition Corp. Files for a $150M SPAC
by Kristi Marvin on 2018-11-21 at 7:15am

The SPAC decks were recently cleared with three pricings last week and have immediately been replenished with three new filings.  The first was CF Finance, then on Monday we had Monocle for $150 million, and now on Tuesday evening, Schultze Special Purpose Acquisiton Corp (SAMAU), also filed for a $150 million SPAC.  Schultze (SAMAU), which is focusing on companies that have been financially restructured, is being sponsored by Schultze Asset Management, LP, an alternative investment management firm who’s strategy is based on the belief that distressed securities can often be purchased at discounts to intrinsic value given the complexities surrounding their restructuring.

Schultze Special Purpose Acquisition Corp. is being led by the eponymous George Schultze, as Chairman, CEO and President and is a well known figure in the distressed and bankruptcy investment industry having authored “The Art of Vulture Investing: Adventures in Distressed Securities Management“, and is also the founder of Schultze Asset Management, LP.

Looking at this SPAC’s structure, once again we see a 100% in trust, one share + one warrant deal, but with 18 months to find an acquisition. Further details below.

Schultze Table

These terms feel to be the standard lately and reflect the current climate. The market is tight and there’s not a lot of wiggle room for SPACs so these terms feel appropriate. Plus, given that Schultze is focusing on companies that are post-restructuring, the Hostess deal with Gores-I immediately comes to mind. If you recall, the Gores team acquired Hostess four years post-bankruptcy when the company’s financial condition was in much better shape. That was a great deal.  Since Schultze has made a career out of finding companies such as Hostess, a SPAC seems like a good fit.

One other quick note – this is the second time this week we’ve seen BTIG make an appearance on a SPAC – first on the CF Finance deal as qualified independent underwriter and now as one of the lead underwriters of Schultze. Keep an eye on them for the 2019 League Tables.  They are part of a new crop of underwriters, such as BAML, Jefferies and Macquarie, that are making moves.

EarlyBirdCapital and BTIG are joint lead underwriting managers.
Greenberg Traurig, LLP and Graubard Miller are issuer’s counsel and underwriter’s counsel, respectively.

Recent Posts
by Nicholas Alan Clayton on 2024-04-18 at 11:50am

AGBA (NASDAQ:AGBA) stock is up over +90% this morning following a +211% premarket spike on news it has signed a definitive agreement to combine with social streaming video platform Triller. AGBA, the company itself, was formed by the $555 million combination between a SPAC of the same name and TAG Companies, a financial services firm...

by Nicholas Alan Clayton on 2024-04-18 at 7:57am

At the SPAC of Dawn Since closing its combination with DHC last month, AI customer engagement firm BEN (NASDAQ:BNAI) has rolled out new partnerships with call center and healthcare clients. And, while it faces a fair bit of competition in the chatbot realm, several high-profile institutions have demonstrated that creating one that provides useful services...

by Nicholas Alan Clayton on 2024-04-17 at 3:05pm

Blue Ocean (NASDAQ:BOCN) provided significantly more texture today in the presentation for its $275 million combination with Asian digital media group TNL Mediagene, which it expects to hit profitability in the second half of the year despite a slight shakeup in financing for the transaction. The first big update in the first investor deck is...

by Nicholas Alan Clayton on 2024-04-17 at 8:13am

At the SPAC of Dawn A brand new market may have just opened up for space de-SPACs as NASA administrator Bill Nelson announced a shift in the agency’s $11 billion program for a mission to return samples from Mars. Rather than rely on the agency’s internal technologies that would be predicted to get a sample...

by Nicholas Alan Clayton on 2024-04-16 at 11:33am

Overall deal flow between SPACs and biotech firms has slowed over the last year, but some pending FDA changes could breathe new life into particular business models within the space. In particular, the FDA has asked Congress as part of its 2025 Legislative Proposals to eliminate the interchangeability designation for biosimilar medications, claiming the existing...

logo

Copyright © 2023 SPACInsider, Inc. All Rights Reserved